Clinical Trial: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06943755) titled 'Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors' on April 17.

Brief Summary: The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Pancreatic Neuroendocrine Tumor (pNET) Extra-Pancreatic Neuroendocrine Tumor (epNET)

Intervention: DRUG: Zanzalintinib

Administered as specified in the treatment arm.

DRUG: Everolimus

Administered as specified in t...